AIFF (Firefly Neuroscience) FCF Margin % : -14,239.39% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Firefly Neuroscience FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Firefly Neuroscience's Free Cash Flow for the three months ended in Sep. 2024 was $-4.70 Mil. Firefly Neuroscience's Revenue for the three months ended in Sep. 2024 was $0.03 Mil. Therefore, Firefly Neuroscience's FCF Margin % for the quarter that ended in Sep. 2024 was -14,239.39%.

As of today, Firefly Neuroscience's current FCF Yield % is -17.33%.

The historical rank and industry rank for Firefly Neuroscience's FCF Margin % or its related term are showing as below:

AIFF' s FCF Margin % Range Over the Past 10 Years
Min: -11937.5 Med: -11937.5 Max: -242.59
Current: -242.59

During the past 2 years, the highest FCF Margin % of Firefly Neuroscience was -242.59%. The lowest was -11937.50%. And the median was -11937.50%.

AIFF's FCF Margin % is ranked worse than
95.16% of 2747 companies
in the Software industry
Industry Median: 2.19 vs AIFF: -242.59

Firefly Neuroscience FCF Margin % Historical Data

The historical data trend for Firefly Neuroscience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firefly Neuroscience FCF Margin % Chart

Firefly Neuroscience Annual Data

Trend

Dec21

Dec22

FCF Margin %

-11,937.50

Firefly Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Jun23	Sep23	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial			-	-	2,139.13	-	-14,239.39

Competitive Comparison of Firefly Neuroscience's FCF Margin %

For the Software - Application subindustry, Firefly Neuroscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firefly Neuroscience's FCF Margin % Distribution in the Software Industry

For the Software industry and Technology sector, Firefly Neuroscience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Firefly Neuroscience's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Firefly Neuroscience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Firefly Neuroscience's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-2.892	/	0
	=	%

Firefly Neuroscience's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-4.699	/	0.033
	=	-14,239.39 %

Firefly Neuroscience FCF Margin % Related Terms

Thank you for viewing the detailed overview of Firefly Neuroscience's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Firefly Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Firefly Neuroscience Inc (NAS:AIFF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Military Road, Kenmore, NY, USA, 14217

Website

https://fireflyneuro.com

Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders.